Related Experiment Video
Updated: Jul 5, 2026
06:21
Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
CYP450 pharmacogenetics for personalizing cancer therapy
1Department of Clinical Chemistry, Erasmus University Medical Center, 's-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands. r.vanschaik@erasmusmc.nl
Summary
Genetic factors influence drug metabolism, impacting cancer treatment efficacy and toxicity. Understanding cytochrome P450 genetic polymorphisms enables personalized medicine, optimizing drug dosing and selection for better patient outcomes.
Area of Science:
- Pharmacogenetics
- Oncology
- Drug Metabolism
Background:
- Individual drug response varies due to genetic differences in drug absorption and metabolism.
- Cytochrome P450 enzymes play a crucial role in drug metabolism, and their activity is influenced by genetic polymorphisms.
- Identifying relevant genetic variations is key to predicting patient response to drug therapy.
Purpose of the Study:
- To review current knowledge on cytochrome P450 genetic polymorphisms in cancer treatment.
- To highlight the potential of pharmacogenetics for personalized cancer therapy.
- To discuss the clinical implications of cytochrome P450 pharmacogenetics for specific cancer drugs.
Main Methods:
- Literature review of cytochrome P450 genetic polymorphisms and their impact on cancer drug efficacy and toxicity.
- Analysis of pharmacogenetic data for specific anticancer agents.
- Discussion of individualized dosing and drug selection strategies based on genetic profiles.
Main Results:
- Numerous cytochrome P450 genetic polymorphisms have been identified, affecting drug metabolism.
- Pharmacogenetic analysis can predict patient response to various cancer therapies.
- Personalized therapy based on cytochrome P450 genotype can improve treatment efficacy and reduce toxicity.
Conclusions:
- Cytochrome P450 pharmacogenetics offers significant potential for optimizing cancer treatment.
- Individualized therapy based on genetic polymorphisms can enhance drug efficacy and minimize adverse events.
- Further research is needed to fully integrate pharmacogenetic insights into routine clinical practice for cancer patients.
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...